Paige Mahaney's most recent trade in C4 Therapeutics Inc was a trade of 19,200 Common Stock done . Disclosure was reported to the exchange on Oct. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | Paige Mahaney | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2025 | 19,200 | 105,000 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Paige Mahaney | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 28 Oct 2025 | 5,644 | 99,356 | - | 2.6 | 14,562 | Common Stock |
| C4 Therapeutics Inc | Paige Mahaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 42,400 | 42,400 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Paige Mahaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 28,200 | 105,000 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Paige Mahaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2024 | 345,600 | 345,600 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Paige Mahaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2024 | 76,800 | 76,800 | - | 0 | Common Stock |